Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 4.98
CNDO's Cash to Debt is ranked higher than
66% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. CNDO: 4.98 )
CNDO' s 10-Year Cash to Debt Range
Min: 2.76   Max: No Debt
Current: 4.98

F-Score: 3
Z-Score: 3.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -27.63
CNDO's ROE (%) is ranked higher than
75% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. CNDO: -27.63 )
CNDO' s 10-Year ROE (%) Range
Min: -380.1   Max: -26.86
Current: -27.63

-380.1
-26.86
ROA (%) -21.98
CNDO's ROA (%) is ranked higher than
75% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. CNDO: -21.98 )
CNDO' s 10-Year ROA (%) Range
Min: -311.1   Max: -21.47
Current: -21.98

-311.1
-21.47
ROC (Joel Greenblatt) (%) -14986.94
CNDO's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. CNDO: -14986.94 )
CNDO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106572.55   Max: -8277.35
Current: -14986.94

-106572.55
-8277.35
» CNDO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CNDO Guru Trades in Q1 2014

Jim Simons 392,412 sh (+1018.81%)
Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

CNDO Guru Trades in Q2 2014

George Soros 29,279 sh (New)
Jim Simons 523,900 sh (+33.51%)
Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
» More
Q3 2014

CNDO Guru Trades in Q3 2014

Paul Singer 3,731,279 sh (unchged)
Chuck Royce 530,000 sh (unchged)
George Soros Sold Out
Jim Simons 187,719 sh (-64.17%)
» More
Q4 2014

CNDO Guru Trades in Q4 2014

Paul Singer 3,731,279 sh (unchged)
Jim Simons Sold Out
Chuck Royce 467,400 sh (-11.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CNDO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.36
CNDO's P/B is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. CNDO: 2.36 )
CNDO' s 10-Year P/B Range
Min: 0   Max: 61.8
Current: 2.36

0
61.8
EV-to-EBIT -5.92
CNDO's EV-to-EBIT is ranked higher than
84% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CNDO: -5.92 )
CNDO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.92

Current Ratio 17.28
CNDO's Current Ratio is ranked higher than
94% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CNDO: 17.28 )
CNDO' s 10-Year Current Ratio Range
Min: 6.69   Max: 17.28
Current: 17.28

6.69
17.28
Quick Ratio 17.28
CNDO's Quick Ratio is ranked higher than
94% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CNDO: 17.28 )
CNDO' s 10-Year Quick Ratio Range
Min: 6.69   Max: 17.28
Current: 17.28

6.69
17.28

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.36
CNDO's Price/Tangible Book is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. CNDO: 2.36 )
CNDO' s 10-Year Price/Tangible Book Range
Min: 1.06   Max: 11.75
Current: 2.36

1.06
11.75
Earnings Yield (Greenblatt) -16.90
CNDO's Earnings Yield (Greenblatt) is ranked higher than
53% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CNDO: -16.90 )
CNDO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -410.2   Max: 2627.7
Current: -16.9

-410.2
2627.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:CNB.Germany,
Coronado Biosciences Inc was incorporated on June 28, 2006. It is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Its two main product candidates in clinical development are: TSO and CNDO-109. TSO, or CNDO-201, is a biologic comprising Trichuris suis ova, the microscopic eggs of the porcine whipworm. TSO is a biologic product candidate for the treatment of autoimmune diseases. CNDO-109 is a lysate that is disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components that activates donor Natural Killer cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia, or ALL. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Government authorities in the United States, at the federal, state and local level, and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products.
» More Articles for CNDO

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Jul 28 2013 
Weekly CFO Buys Highlight Jul 21 2013 
Weekly CFO Buys Highlight Jun 11 2013 
Weekly CEO Buys Highlight: CNDO Jan 21 2013 
Coronado Biosciences New CEO Makes First Buy of the Year, Worth $114K Jan 16 2013 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 


More From Other Websites
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Jumps 8.6% - Tale of the Tape Mar 25 2015
CORONADO BIOSCIENCES INC Financials Mar 21 2015
Stocks sold off on Thursday — except for the one sector people are calling a bubble Mar 19 2015
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership with the... Mar 19 2015
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership With the... Mar 19 2015
Coronado Biosciences Announces Exclusive Licensing Agreement with NeuPharma to Develop and... Mar 19 2015
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and... Mar 19 2015
CORONADO BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 18 2015
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Mar 16 2015
CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 16 2015
Coronado reports 4Q loss Mar 16 2015
Coronado reports 4Q loss Mar 16 2015
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Mar 16 2015
TG Therapeutics-Coronado Sign Up Immuno-Oncology Deal - Analyst Blog Mar 06 2015
CORONADO BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Mar 05 2015
Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology... Mar 04 2015
TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and... Mar 04 2015
Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology... Mar 04 2015
TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and... Mar 04 2015
Coronado Biosciences Closes $10 Million Private Placement Financing Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK